like compani confid long-term
target growth acceler driven invest higher
growth area rais price target estim
accordingli howev quarter guid wasnt clean enough
move us sidelin dont think move stock
much higher given lofti expect rich multipl
posit side growth discoveri analyt da growth look
good euroimmun seem go well updat current fx
give compani tailwind guid guid rate
would look favor addit portfolio
trim hint neg side
margin great explain
acquisit tax reform turn headwind expect
modest tailwind guidanc significantli
quick take quarter beat revenu ep consensu
rel consensu believ appropri use
report ep instead face press
releas use basic rather dilut sharecount
highlight quarter strong organ revenu discoveri
analyt solut da strong acquir revenu diagnost
da grew organ diagnost grew organ
euroimmun acquisit close contribut
beat drag margin due increas compens
charg exclud charg oper margin would
closer consensu exhibit full varianc analysi
guidanc guidanc came consensu
guidanc consensu manag expect revenu
midpoint organ revenu growth
exclud euroimmun expect grow gross margin
expect expand oper margin expand
net interest expens expect increas
due financ cost relat euroimmun effect tax
rate expect bp increas due tax reform
bp jurisdict mix ep project
accret euroimmun midpoint
exhibit full guidanc
read-through believ strong organ growth da read
posit rest tool group strong pharma
end market low doubl digit impress
environment low doubl digit food high singl
digit think clearest posit read-through agil
compani data secur llc estim reuter
exclud amort acquir intang asset one-tim restructur
compani prioriti stock list
compani data secur llc estim reuter
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
report date estactualconsyr gener interest incom expens incom incom continu non-gaap declar per dilut share margin analysisyr yrseqgross bpssg bpsr bpsoper bpspretax bpstax bpsnet margin continu bpsebitda bpssegment analysisyr yrseqdiscoveri analyt solut bpsgrowth bpsgrowth bpsgrowth bpsoper margin bpsgrowth bpsgrowth bpsgrowth bpsoper margin bpstotal net growth bpstotal growth bpstotal growth bpstotal revenu bpscorpor bpssourc compani data factset secur llc estimatesin mm except epsactualfi end inc
priorcurrentchangepriorcurrentchangetot gener incom expens incom incom continu declar per share margin analysisgross bpssg bpsr bpsoper bpspretax bpstax bpsnet margin continu bpsebitda bpssegment analysisdiscoveri analyt solut bpsgrowth bpsgrowth bpsgrowth bpsoper margin bpsgrowth bpsgrowth bpsgrowth bpsoper margin bpstotal net growth bpstotal growth bpstotal growth bpstotal revenu bpscorpor compani data secur llc estimatesfi end mm except life scienc tool servic diagnost
euroimmun fxrevenu growth organ organ ei core da organicgross bm ga dnet interest exens tax bp tax reform bp jurisdict hwsharecount accret euroimmunsourc compani estim secur llcda low flow margin diagnost typic guid fx rate end prior long term oper bp gm bp cagrcapit acquisit biassourc compani estim secur llc inc
perkinelm quarterli data fy end decemb million except per gross sell gener research oper interest incom expens pre-tax provis incom net incom continu non-gaap dividend declar per dilut share gross margin continu gener incom continu share analyt solut growth oper margin growth oper margin net total growth growth growth revenu total net cash debt ttm debt ttm flow capit free cash free cash flow per compani report secur llc estimatesmargin analysisseg analysischang analysi y/i non-gaap incom statement life scienc tool servic diagnost
price target
price target dcf-base wacc termin noplat growth repres fy
ep estim upsid risk thesi includ clean execut euroimmun would like
acceler revenu growth profil continu portfolio ration enhanc growth margin
cash flow aggress return capit downsid risk thesi includ integr
challeng sudden downturn key end market disrupt diagnost sale emerg market
increas competit key product
success improv oper result past year compani also
embark clinic diagnostics-focus strategi interest opportun emerg
market far larg eroimmun deal seem go well point mostli valuat
keep us sidelin
waltham -base nyse life scienc tool servic compani
provid human environment healthcar solut diagnost research lab servic appli
scienc industri market organ two report segment discoveri analyt
solut da diagnost da primarili serv life scienc end market well industri
environment food diagnost segment particip reproduct health infecti diseas
oncology/appli genom
